Randomized Trials
Cumulative 5-year results of a randomized controlled trial comparing biological Mesh with primary perineal wound closure after extralevator abdominoperineal resection.
20 Jan, 2022 | 08:40h | UTCCumulative 5-year Results of a Randomized Controlled Trial Comparing Biological Mesh With Primary Perineal Wound Closure After Extralevator Abdominoperineal Resection (BIOPEX-study) – Annals of Surgery (link to abstract – $ for full-text)
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia.
19 Jan, 2022 | 08:11h | UTCSafety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study – The Lancet Neurology (link to abstract – $ for full-text)
Cluster-randomized trial: Antiseptic bathing with 2% chlorhexidine-impregnated cloths and 0.08% octenidine wash mitts were not effective for preventing central-line associated bloodstream infections in intensive care patients.
18 Jan, 2022 | 09:18h | UTC
Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.
18 Jan, 2022 | 09:11h | UTC
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.
18 Jan, 2022 | 09:10h | UTCRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.
16 Jan, 2022 | 23:13h | UTCThe D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.
16 Jan, 2022 | 23:11h | UTCNews Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT: In patients undergoing emergency endotracheal intubation, 7-day survival was significantly lower with etomidate vs. ketamine (77.3% versus 85.1%), but 28 survival rates were not significantly different (etomidate 64.1% vs. ketamine 66.8%, p = 0.294).
16 Jan, 2022 | 23:09h | UTC
Commentary on Twitter
Etomidate vs ketamine for emergency endotracheal intubation, RCT
💉801 critically ill pts assigned to receive etomidate (0.2–0.3 mg/kg) or ketamine (1–2 mg/kg)
💉day 7 survival significantly lower with etomidate
💉no significantly different day 28 survivalhttps://t.co/CkxufORC8A pic.twitter.com/xQ4AtCifc7— Intensive Care Medicine (@yourICM) December 17, 2021
RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.
16 Jan, 2022 | 23:01h | UTCNews Release: ECT more effective than ketamine in severe depression – Lund University
Commentary on Twitter
RCT-OL: 63% of inpatients with MDD receiving ECT remitted vs. 46% receiving ketamine infusions (p=0.026). Both ketamine and ECT required a median of 6 sessions to induce remission. Long-lasting AE include persisting amnesia with ECT https://t.co/tvJ0qwUu62 pic.twitter.com/NOQK8Xv8TW
— P𝘧OL (@psychopharmacol) December 12, 2021
Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.
16 Jan, 2022 | 22:59h | UTC
RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19.
14 Jan, 2022 | 08:35h | UTCRelated:
M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.
Commentary on Twitter
This randomized clinical trial found that colchicine did not significantly reduce mechanical ventilation or mortality in patients hospitalized with #COVID19 pneumonia. @DLBhattMD https://t.co/2nU5Ks74uF pic.twitter.com/VvHhTFnBhV
— JAMA Network Open (@JAMANetworkOpen) December 29, 2021
RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.
14 Jan, 2022 | 08:15h | UTC
Commentary on Twitter
In poorly controlled #ParkinsonDisease, study found adding a COMT inhibitor to existing treatment is not as good as adding a MAOB inhibitor or dopamine agonist https://t.co/0GrA2YYMbI pic.twitter.com/d4VNnom2zk
— JAMA Neurology (@JAMANeuro) December 28, 2021
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
RCT: In patients with acromegaly who previously tolerated and responded to both regimens, oral octreotide was non-inferior for maintaining biochemical response and symptomatic control compared to injectable somatostatin receptor ligands.
14 Jan, 2022 | 07:55h | UTCMaintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.
13 Jan, 2022 | 08:54h | UTCEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Commentary on Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
RCT: Pancreatoduodenectomy with or without prophylactic falciform ligament wrap around the hepatic artery for prevention of postpancreatectomy haemorrhage.
13 Jan, 2022 | 08:35h | UTCPancreatoduodenectomy with or without prophylactic falciform ligament wrap around the hepatic artery for prevention of postpancreatectomy haemorrhage: randomized clinical trial (PANDA trial) – British Journal of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
In Jan's BJS: Pancreatoduodenectomy with/without prophylactic falciform ligament wrap around hepatic artery: PANDA trial https://t.co/itf6rQsxMP @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/YpBocbplUn
— BJS (@BJSurgery) January 11, 2022
RCT: In full-term and near-term neonates, drug treatment of all clinically and electrographically detected seizures was not associated with reduced death rates or disability at 2 years compared with the treatment of only the clinically detected seizures.
13 Jan, 2022 | 08:24h | UTCCommentaries:
Should we treat electrographic seizures? – Neonatal Research
Subclinical Electrographic Seizures in the Newborn—Is More Treatment Better? – JAMA Network Open
Neonatal Seizures: Little Difference Between EEG/Clinical Treatment – Physician’s Weekly
Commentary on Twitter
NEST trial in @JAMANetworkOpen by @rodwhunt explores if treatment of EEG + clinical seizures compared with only treating clinical seizures in encephalopathic infants decreased odds of severe disability at 2 years of age. https://t.co/s3yYi6R3fV #EBNEOalerts #neoEBM #neotwitter pic.twitter.com/xoxVKC2a5z
— Evidence-Based Neo (@EBNEO) December 29, 2021
RCT: Eltrombopag added to immunosuppression is associated with improved hematologic response vs. immunosuppression alone in previously untreated patients with severe aplastic anemia.
12 Jan, 2022 | 08:46h | UTCEltrombopag Added to Immunosuppression in Severe Aplastic Anemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A randomized trial comparing immunosuppression (horse ATG and cyclosporine) with the same therapy plus eltrombopag showed more rapid and complete responses with the addition of eltrombopag. https://t.co/nH7rkeCMAS pic.twitter.com/i8iTIq8FSG
— NEJM (@NEJM) January 5, 2022
Phase 2 RCT: Adjunctive ketamine with relapse prevention–based psychological therapy shows promise for the treatment of alcohol use disorder.
12 Jan, 2022 | 08:42h | UTCAdjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary: People With AUD May Benefit From Combination of Ketamine, Mindfulness Therapy – Psychiatric News Alert
RCT: Among patients with short bulbar urethral strictures, those submitted to transecting excision and primary anastomosis (tEPA) reported more penile complications compared to patients submitted to buccal mucosa grafting (BMG).
12 Jan, 2022 | 08:39h | UTC
Commentary on Twitter
To Transect or Not Transect: Results from the Scandinavian Urethroplasty Study, A Multicentre Randomised Study of Bulbar Urethroplasty Comparing Excision and Primary Anastomosis Versus Buccal Mucosal Graftinghttps://t.co/pO7MS7F65H@veiby_holm @7some pic.twitter.com/Vy4wmc74ul
— European Urology (@EUplatinum) January 10, 2022
RCT: Interferon-alpha vs. Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.
12 Jan, 2022 | 08:35h | UTC
RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.
11 Jan, 2022 | 02:29h | UTCEarly Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)